PD-L1 and tumor-associated macrophages in de novo DLBCL

Area of Science:

• Immunology
• Oncology
• Pathology

Background:

• Programmed death-ligand 1 (PD-L1) and programmed cell death-1 (PD-1) regulate immune activation.
• Single-agent PD-1/PD-L1 therapy shows limited efficacy in diffuse large B-cell lymphoma (DLBCL).
• Understanding PD-L1 biology and assays is crucial for DLBCL treatment strategies.

Purpose of the Study:

• To investigate the biologic and clinical relevance of PD-L1 in de novo DLBCL.
• To analyze PD-L1 expression patterns in DLBCL patient cohorts.
• To identify potential correlations between PD-L1 and patient outcomes or specific molecular pathways.

Main Methods:

• Analysis of PD-L1 expression using samples from two large de novo DLBCL phase 3 trials (GOYA and MAIN).
• Assessment of PD-L1 localization (myeloid vs. tumor cells) and correlation with gene expression profiles.
• Statistical analysis to determine the relationship between PD-L1 expression, clinical risk, and patient outcomes.

Main Results:

• PD-L1 was expressed on myeloid cells in 85-95% of DLBCL patients, contrasting with 10% on tumor cells.
• PD-L1 expression correlated with macrophage gene expression signatures.
• PD-L1 did not identify high-risk DLBCL patients but was associated with improved outcomes in a subset, linked to STAT3 and macrophage pathways.

Conclusions:

• PD-L1 expression in DLBCL is predominantly on myeloid cells and linked to macrophage biology.
• PD-L1 is not a reliable biomarker for high-risk DLBCL but may indicate a subset with favorable prognosis.
• Findings may aid in identifying DLBCL subsets for targeted immunotherapy, including checkpoint blockade.